Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs containing GLP-1, a hormone that slows digestion and helps with sustained ...

Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide — are now available in the Indian market. Here’s how they work, how ...

Novo Nordisk has launched its weight-loss drug Wegovy in India, while Eli Lilly's Mounjaro has received regulatory approval, ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

In his new book, a former FDA commissioner unpacks the latest science on metabolism, weight loss, and how GLP-1 drugs ...

GLP-1 analogs have been widely used to treat patients with type 2 diabetes in recent years ... 8–12% SDS–PAGE was used to resolve equivalent amounts of protein and was then transferred to ... 40, 65, ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

India’s health regulator has approved Eli Lilly’s pre-filled pen version of Mounjaro, expanding its availability across six ...